

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

Mouse Anti-Human IgG2 Fc-HRP

RRID:AB_2796633

Type: Antibody

Proper Citation

SouthernBiotech Cat# 9060-05, RRID:AB_2796633

Antibody Information

URL: http://antibodyregistry.org/AB_2796633

Proper Citation: SouthernBiotech Cat# 9060-05, RRID:AB_2796633

Target Antigen: IgG2 Fc

Host Organism: mouse

Clonality: monoclonal

Comments: Original manufacturer of this product; ISO 9001:2015

Antibody Name: Mouse Anti-Human IgG2 Fc-HRP

Description: This monoclonal targets IgG2 Fc

Target Organism: human

Clone ID: Clone 31-7-4

Antibody ID: AB_2796633

Vendor: SouthernBiotech

Catalog Number: 9060-05

Record Creation Time: 20250819T231808+0000

Record Last Update: 20250820T045456+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-Human IgG2 Fc-HRP.

No alerts have been found for Mouse Anti-Human IgG2 Fc-HRP.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Clark JJ, et al. (2026) Cross-binding antibodies capable of neutralising diverse hantaviruses are produced in response to Puumala virus infection. EBioMedicine, 106091.

Gonzalez-Miro M, et al. (2023) Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trial. iScience, 26(3), 106261.

Emmenegger M, et al. (2022) Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants. iScience, 25(8), 104766.

Wang EY, et al. (2022) High-throughput identification of autoantibodies that target the human exoproteome. Cell reports methods, 2(2).

Dugan HL, et al. (2021) Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity, 54(6), 1290.

Honjo K, et al. (2021) Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. Cell reports. Medicine, 2(1), 100164.

Galipeau Y, et al. (2021) Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2. EBioMedicine, 74, 103700.

Kim DM, et al. (2021) Enhanced eosinophil-mediated inflammation associated with antibody and complement-dependent pneumonic insults in critical COVID-19. Cell reports, 37(1), 109798.

Wieland A, et al. (2021) Defining HPV-specific B cell responses in patients with head and neck cancer. Nature, 597(7875), 274.

Farkash I, et al. (2021) Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern. Cell reports, 37(11), 110114.

Gruber CN, et al. (2020) Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell, 183(4), 982.

Suthar MS, et al. (2020) Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell reports. Medicine, 1(3), 100040.

Davis CW, et al. (2019) Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection. Cell, 177(6), 1566.